Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patien… (NCT07718139) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
United Kingdom300 participantsStarted 2026-02-28
Plain-language summary
This study uses existing medical records to better understand how immunotherapy is used in people in Europe and Canada with non-small cell lung cancer (NSCLC) who undergo surgery. It looks at participant characteristics, treatments received before and after surgery, and outcomes such as survival.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosed with non-small-cell lung cancer (NSCLC) stage IIA to IIIB
* Participants aged ≥18 years at time of NSCLC diagnosis
* Initiated and received neoadjuvant nivolumab or neoadjuvant phase of perioperative immunotherapy during the patient inclusion period
* Documented record of curative surgical resection following receipt of neoadjuvant nivolumab or neoadjuvant phase of perioperative immunotherapy
* NSCLC is assessed as resectable by a clinician, surgeon, or multidisciplinary team.
Exclusion Criteria:
• Diagnosis of another primary malignancy (excluding non-melanoma skin cancer) within 5 years prior to NSCLC diagnosis or at any time after diagnosis
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of participants with pathological complete response after neoadjuvant immunotherapy and surgical resection.
Timeframe: Up to 14 months
2
Number of participants with major pathological response after neoadjuvant immunotherapy and surgical resection.
Timeframe: Up to 14 months
3
Number of participants with post-operative complications following surgical resection
Timeframe: Up to 90 days
4
Number of participants by surgical resection margin status
Timeframe: Up to 14 months
5
Number of participants by surgical resection type
Timeframe: Day 1
6
Number of participants by surgical approach
Timeframe: Day 1
7
Number of participants with all-cause mortality within 90 days after surgery